Astria Therapeutics Inc's Business Segments

A biopharmaceutical company is focused on discovering, developing, and commercializing novel therapeutics. The company's mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. The lead product candidate is STAR-0215, a potential best-in-class monoclonal antibody inhibitor of plasma kallikrein in clinical development for the treatment of hereditary angioedema (HAE). The company aims to develop STAR-0215 as a best-in-class monoclonal antibody inhibitor of plasma kallikrein able to provide long-acting, effective attack prevention for HAE with dosing once every three months or potentially less frequently. The company believes that STAR-0215 has the potential to become the first-choice preventative treatment for HAE with administration every three or six months, thus normalizing the lives of people living with HAE. The company has submitted an Investigational New Drug application for STAR-0215 and cleared by the FDA for clinical development. The company initiated a Phase 1a clinical trial, which showed that STAR-0215 was well-tolerated at all dose levels, with no serious adverse events or discontinuations due to an adverse event. Additionally, STAR-0215 demonstrated rapid and sustained drug levels with dose-dependent PK and an estimated half-life of up to 117 days. The company is evaluating the potential for 6-month dosing with additional healthy subject cohorts in the Phase 1a trial with initial results expected in the fourth quarter of 2023. The company has initiated a global, multi-center, open-label, single and multiple dose proof-of-concept clinical trial in people with HAE called ALPHA-STAR to evaluate the safety, tolerability, HAE attack rate, PK, PD, and quality of life in patients three and six months after STAR-0215 administration. The company believes that STAR-0215 has the potential to be a best-in-class monoclonal antibody inhibitor of plasma kallikrein that could combine the benefits of infrequent dosing with the inhibition of attacks over long periods of time.

Astria Therapeutics Inc is a biopharmaceutical company dedicated to developing and commercializing innovative therapies to target a variety of diseases. The company is structured into several key segments, each representing a focus area in their research and therapeutic offerings. Below is an extensive overview of its segments, products, and services.

Segments:

1. Neurology:
- This segment is dedicated to tackling neurological disorders, which can significantly impact patients quality of life. Astria Therapeutics is developing treatments for conditions such as:
- Parkinsons Disease: A progressive neurological disorder that affects movement.
- Alzheimers Disease: A form of dementia that leads to cognitive decline and memory loss.
- Multiple Sclerosis: An autoimmune disease affecting the central nervous system that can cause a wide range of symptoms, including fatigue, mobility issues, and cognitive changes.

2. Oncology:
- Astria Therapeutics is also focused on oncology, where they are researching therapies aimed at various forms of cancer. The target indications within this segment include:
- Breast Cancer: One of the most common types of cancer among women, with various subtypes requiring different treatment approaches.
- Lung Cancer: A leading cause of cancer deaths, requiring innovative therapies for both small cell and non-small cell lung cancers.
- Pancreatic Cancer: Known for its poor prognosis, research efforts focus on developing targeted treatment strategies.

3. Rare Diseases:
- The company is committed to addressing the unmet needs of patients suffering from rare diseases, including:
- Gaucher Disease: A genetic disorder characterized by the accumulation of fatty substances in certain organs.
- Fabry Disease: A rare genetic disorder leading to the buildup of globotriaosylceramide in the body, causing various systemic effects.
- Pompe Disease: A metabolic disorder caused by the buildup of glycogen in the body’s cells.

4. Immunology:
- In the field of immunology, Astria Therapeutics is developing therapies for a range of immune-related disorders, including:
- Rheumatoid Arthritis: An autoimmune condition that primarily affects the joints, leading to pain and inflammation.
- Psoriasis: A chronic autoimmune skin condition characterized by red, scaly patches on the skin.
- Lupus: A systemic autoimmune disease that can affect multiple organ systems.

Products:

1. ATP-200:
- A small molecule drug designed specifically for treating Parkinsons disease. ATP-200 enhances dopamine release in the brain, aimed at alleviating the motor symptoms typically associated with the disease.

2. ATP-400:
- This small molecule is being developed for Alzheimers disease, focusing on reducing the aggregation of amyloid beta proteins, which are implicated in the pathogenesis of the disease.

3. ATP-300:
- Targeted towards multiple sclerosis, ATP-300 works by decreasing inflammation and demyelination of nerve fibers, addressing one of the primary mechanisms behind the disease.

4. ATP-500:
- Under development for breast cancer treatment, ATP-500 is designed to target cancer stem cells, which play a key role in cancer recurrence and metastasis.

Services:

1. Clinical Trials:
- Astria Therapeutics conducts a range of clinical trials to evaluate the safety and efficacy of its therapies. Their clinical trial services encompass study design, patient recruitment, and ongoing monitoring to ensure robust results.

2. Drug Discovery:
- The company offers comprehensive drug discovery services that include:
- Target identification, where potential new drug targets are discovered.
- Lead optimization, refining promising candidates for further development.
- Preclinical development, laying the groundwork for subsequent clinical studies.

3. Contract Manufacturing:
- Astria Therapeutics provides contract manufacturing services, enabling other biopharmaceutical companies to produce small molecule drugs and biologics efficiently and at scale.

4. Licensing:
- Through licensing arrangements, Astria Therapeutics shares its technology and intellectual property with other firms in the biopharmaceutical sector, supporting the broader development of new therapies.

Summary:
Astria Therapeutics Inc presents a varied portfolio that spans multiple therapeutic areas, focusing on delivering innovative solutions for complex medical challenges. The company’s continued commitment to research, coupled with its clinical, manufacturing, and licensing capabilities, positions it as a vital player in the biopharmaceutical landscape, aiming to improve health outcomes and the quality of life for patients across different disease domains.